Is Travere Therapeutics (TVTX) Undervalued After Its Mixed Q3 2026 Results?

Travere Therapeutics (TVTX) just released third quarter 2026 results, pairing higher reported revenue with a swing to loss. The update gives you fresh numbers to reassess this rare disease specialist.

The Travere Therapeutics share price has slipped over the past month, with a 30 day share price return of down 13.47% and a 90 day move of down 12.07%, as investors weigh the wider quarterly loss, CEO transition and recent FILSPARI data. Even with that pullback, the year to date share price return is up 24.65% and the 1 year total shareholder return is 42.66%. The 3 year total shareholder return is very large at more than 7x, and the 5 year total shareholder return is 64.20%, which signals that momentum remains positive over longer horizons despite the near term volatility.

Spot 19 high quality undiscovered gems that, like Travere Therapeutics after this mixed Q3 update, combine active pipelines with under the radar share price moves.

Travere Therapeutics now trades at a steep discount to both analyst targets and some intrinsic value estimates, even after the earnings miss and CEO change. Is the market being prudent about the losses, or is it mispricing the pipeline potential?

Most Popular Narrative: 34% Undervalued

Travere Therapeutics last closed at $49.26. The most followed narrative points to a fair value of about $74.14, using a 7.53% discount rate and analyst growth assumptions to bridge that gap.

Travere's strengthening financial position, driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management, sets a foundation for positive net earnings, while securing resources for continued pipeline development and future commercial launches.

See why 23 investors see Travere Therapeutics as 34% undervalued.

Result: Fair Value of $74.14 (UNDERVALUED)

Still, Travere Therapeutics leans heavily on FILSPARI, so any regulatory setback or slower-than-modeled adoption could quickly challenge this 34% undervalued narrative.

Find out about the key risks to this Travere Therapeutics narrative.

Next Steps

That mix of optimism and caution only gets you so far without your own work. Act on the data while it is fresh and pressure test those 4 key rewards.

Hunting For More Ideas Beyond Travere Therapeutics?

Do not stop at one opportunity. Broader context across sectors and styles helps you decide where Travere Therapeutics belongs in your portfolio and what might sit alongside it.

Use the Simply Wall St screener to quickly surface other candidates that match different goals and risk profiles before the market moves on.

• Target potential mispriced opportunities by scanning our current pool of 34 high quality undervalued stocks that combine solid fundamentals with discounted share prices.
• Prioritise resilience by checking a list of solid balance sheet and fundamentals (24 results) so you can focus on businesses with stronger financial footing when conditions change.
• Limit downside surprises by filtering for 29 resilient stocks with low risk scores that score well on stability and fewer red flags.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com